Extended Data Fig. 6: Phenotyping data of tumor infiltrating CD8 T cells from orthotopic PPSM tumors, degarelix treated, and enzalutamide + anti-PD-L1 treated.
From: Androgen receptor activity in T cells limits checkpoint blockade efficacy
a–d, PPSM tumor bearing animals were treated as in Fig 3a. CD8 T cell number (a), Ki67 expression (b), PD-1 MFI (c) and CD44 MFI (d) in CD8 T cells in the tumor the day after the 3rd treatment with α-PD-L1. Data representative of 3 independent experiments with 3 animals per group. e–g, PPSM tumor cells were surgically injected orthotopically in the prostate, and orchiectomy was performed. One week later, animals were treated with enzalutamide only or enzalutamide + α-PD-L1 (5 animals per group). 4 weeks post tumor inoculation, tumors were harvested and processed for flow cytometry. Graphs show percent IFNγ+ (e), TNFα+ (f) and IFNγ+TNFα+ double producing (g) CD8 T cells in the tumor (n = 5 animals). h–l, PPSM tumor bearing animals underwent ADT (degarelix, 1 dose, d14 post tumor inoculation), enzalutamide (started at d14) and α-PD-L1 (3 doses, d14, 17, 20). Tumors were harvested on day 21 and processed for flow cytometry. Graphs show percent Ki67+ (h), IFNγ+ (i), TNFα+ (j), IFNγ+TNFα+ (k) and granzyme B+ (l) CD8 T cells in the tumor. Data representative of 2 independent experiments with 3 animals per group. m–o, PPSM tumor bearing animals were treated with the same timeline as in Fig. 3a, but with enzalutamide + α-PD-L1 or ADT + α-PD-L1. Tumors were harvested the day after the 3rd dose of α-PD-L1 and processed for flow cytometry. m, Percent granzyme B+ CD8 T cells in the tumor. n, Representative flow cytogram showing IFNγ and TNFα expression in CD8 T cells in the tumor, and o, Summarized percent IFNγ+TNFα+ CD8 T cells in the tumor. Data representative of 2 independent experiments with 3 animals per group. Error bars represent S.E.M. Two-tailed unpaired Student t-test.
